4 Results for "

intestinal bowel disorder

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "intestinal bowel disorder" in MCE Product Catalog:

Cat. No.: HY-161440
CAS No.: 3033846-29-3
Target:  

AMPK

Research Areas:  

Inflammation/Immunology

SIK-IN-1 (Compound 53) is an inhibitor for salt-inducible kinase (SIK), which inhibits SIK1, SIK2 and SIK3 with IC50s of 0.1, 0.4 and 1.5 nM, respectively. SIK-IN-1 inhibits the release of TNFa with IC50 of 0.5 nM, stimulates the LPS (HY-D1056) -induced IL-10 release with EC50 of 4 nM in human macrophages .
loading...
    loading...
Cat. No.: HY-161442
CAS No.: 3033845-49-4
Target:  

AMPK

Research Areas:  

Inflammation/Immunology

SIK-IN-3 (Compound 6B) is an inhibitor for salt-inducible kinase (SIK), which inhibits SKI1, SIK2 and SIK3 with IC50s of 0.1, 0.3 and 0.8 nM, respectively. SIK-IN-1 inhibits the release of TNFa with IC50 of 0.6 nM, stimulates the LPS (HY-D1056) -induced IL-10 release with EC50 of 3 nM in human macrophages .
loading...
    loading...
Cat. No.: HY-161441
CAS No.: 3033846-20-4
Target:  

AMPK

Research Areas:  

Inflammation/Immunology

SIK-IN-2 (Compound 45) is an inhibitor for salt-inducible kinase (SIK), which inhibits SKI1, SIK2 and SIK3 with IC50s of 0.1, 0.2 and 0.4 nM, respectively. SIK-IN-2 inhibits the release of TNFa with IC50 of 0.5 nM, stimulates the LPS (HY-D1056) -induced IL-10 release with EC50 of 2 nM in human macrophages .
loading...
    loading...
Cat. No.: HY-15026
CAS No.: 915798-75-3
Target:  

Endogenous Metabolite

Research Areas:  

Inflammation/Immunology

ATB-429, a novel H2S-releasing derivative of mesalamine, demonstrates significant anti-nociceptive and anti-inflammatory effects in models of irritable bowel syndrome (IBS). By releasing hydrogen sulfide (H2S), ATB-429 modulates colorectal distension-induced hypersensitivity in both healthy and postcolitic rats. It attenuates abdominal withdrawal responses and suppresses spinal c-Fos mRNA expression, indicating its potential to alleviate pain associated with gastrointestinal inflammation. Moreover, ATB-429 down-regulates colonic cyclooxygenase-2 and interleukin-1β mRNA expression, effects not observed with mesalamine alone. The mechanism involves ATP-sensitive K+ (KATP) channels, as evidenced by reversal of ATB-429's effects with glibenclamide. These findings suggest ATB-429 could offer therapeutic benefits for managing painful intestinal disorders linked to inflammation .
loading...
    loading...